CDXS at a glance
CODEXIS, INC. (CDXS, SEC CIK 1200375) filed its latest 10-K annual report on March 11, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), CODEXIS, INC. (CDXS) reported revenue of $70.4 million (up 18.6% from FY2024) and a net loss of $44.0 million. Diluted EPS was -$0.50.
- As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding CODEXIS, INC. (CDXS) shares worth $45.3 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by MOORE ALISON on November 16, 2026 of 10,651 shares at $1.14 per share.
- In the last 90 days, CDXS insiders reported 0 open-market purchases ($0) and 4 open-market sales ($31K) on Form 4, a net sale of $31K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $70.4M
- +18.6% vs prior year
- Insiders · 90 days
- 0 buys · 4 sells
- Net −$31K
- 13F holders
- 26 funds
- $45.3M · +0 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Quarterly revenue $19.3M, up $10.7M YoY from $8.6M
- Product revenue $15.7M, up $8.9M, driven by $8.4M higher commercial pharmaceutical enzyme sales
- Product gross margin 74% vs 64% YoY, reflecting a shift toward more profitable products
- Operating loss $7.4M vs $18.9M YoY, net loss $8.1M vs $19.6M
- Cash $29.2M vs $50.8M, operating cash use $30.6M, July equity offering net proceeds $24.9M
Risk Factors
- Newly highlighted compliance risk: U.S. BIOSECURE Act enacted December 2025 could restrict counterparties deemed biotechnology companies of concern
- Most material operational update: ECO GMP Manufacturing Center retrofit begins Q4 2026, with potential permitting delays and cost overruns
- Regulatory risk: FDA could reject the Company’s FDCA exemption, requiring cGMP compliance and potentially halting product distribution
- Market risk: customers contributed 48% of nine-month revenue, increasing exposure to customer losses or reduced purchases
- Financial risk: Trinity LSA includes $7.5 million available through December 15, 2027 and liquidity covenant tied to $400.0 million market capitalization
AI summary of the CDXS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Codexis announced financial results for the quarter ended September 30, 2026
- Full results and management commentary are contained in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 revenue $19.3M vs $8.6M, driven by higher-margin product launches at customer companies
- Product gross margin 74.5% vs 64%, signaling improved mix and stronger near-term profitability
Item 1.01: Entry into a Material Definitive Agreement
- $42.5M funded term loan, with up to $60.0M total borrowing capacity across three tranches
- Variable interest rate floor 10.50%, creating substantial financing expense through November 2030
Item 1.02: Termination of a Material Definitive Agreement
- Innovatus Loan Agreement terminated after full repayment of approximately $43.6 million
- Payoff funded by Tranche A Loan proceeds and cash on hand
Item 2.03: Creation of a Direct Financial Obligation
- Item 2.03 points investors to the Loan and Security Agreement described under Item 1.01
- The agreement creates a direct financial obligation for Codexis, with terms and amount requiring review of the referenced exhibit
Item 3.02: Unregistered Sales of Equity Securities
- Lender Warrants issued to financing counterparties through private-placement exemptions under Section 4(a)(2) and Rule 506
- Warrants and underlying common shares unregistered, limiting resale absent SEC registration or another exemption
Item EX-99.1: Item EX-99.1
- Q2 revenue $14.9M versus $15.3M, while product revenue rose to $13.2M from $7.4M
- Product gross margin improved to 73% from 72%, reflecting stronger mix toward newer, higher-margin products
Item 2.02: Results of Operations and Financial Condition
- Codexis announced financial results for the quarter ended June 30, 2026
- Full results and management commentary are contained in Exhibit 99.1
AI summaries of CDXS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CDXS
Don't miss the next CDXS filing
- Alerts as it files. A push when CDXS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CDXS, by share count.
- Ask anything. An AI agent that reads every CDXS filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| MOORE ALISON | Sell | Nov 16, 2026 | 10,651 | $1.14 |
| De Vre Raymond | Sell | Nov 9, 2026 | 1,088 | $1.11 |
| Erbez Georgia | Sell | Oct 12, 2026 | 6,335 | $1.36 |
| MOORE ALISON | Sell | Oct 12, 2026 | 6,335 | $1.36 |
| DILLY STEPHEN GEORGE | A | Jun 17, 2026 | 66,350 | - |
| Smith David V | A | Jun 17, 2026 | 66,350 | - |
| Collins Cynthia | A | Jun 17, 2026 | 66,350 | - |
| De Vre Raymond | A | Jun 17, 2026 | 66,350 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $59.3M | $70.4M |
| Operating Income | - | -$58.5M | -$41.7M |
| Net Income | -$76.2M | -$65.3M | -$44.0M |
| Op. Margin | - | -98.6% | -59.3% |
| Net Margin | - | -110.0% | -62.5% |
| Balance Sheet | |||
| Total Assets | $136.6M | $149.0M | $147.8M |
| Equity | - | $66.9M | $50.5M |
| ROE | - | -97.5% | -87.0% |
| Per Share | |||
| EPS | $-1.12 | $-0.89 | $-0.50 |
| Cash Flow | |||
| Operating CF | - | -$49.4M | -$19.4M |
| CapEx | $4.4M | $4.3M | $4.5M |
Source: XBRL data in CODEXIS, INC. (CDXS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CDXS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 26 | $45.3M |
| Q2 2026 | 26 | $69.1M |
| Q1 2026 | 27 | $44.1M |
| Q4 2025 | 23 | $43.0M |
| Q3 2025 | 24 | $61.5M |
| Q2 2025 | 25 | $60.4M |
| Q1 2025 | 20 | $46.0M |
| Q4 2024 | 16 | $72.0M |
- BlackRock+1.03M (+14%)
- Vanguard Capital Management LLC+727.1K (+20%)
- D.E. Shaw & Co+444.0K (+33%)
- Goldman Sachs Group+405.9K (+93%)
- T. Rowe Price Group+354.4K (+530%)
- Millennium Management−779.5K (-14%)
- Ameriprise Financial−754.2K (-20%)
- State Street Corp−121.4K (-7%)
- Dimensional Fund Advisors−111.9K (-36%)
- AQR Capital Management−75.9K (-9%)
- StoneX Group Inc.+16.9K
- FMR LLC (Fidelity)−478.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 187 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CDXS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 18, 2026 | - | - | - |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 4 | Nov 10, 2026 | - | - | - |
| 4 | Oct 14, 2026 | - | - | - |
| 4 | Oct 14, 2026 | - | - | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| SC 13G | Jul 29, 2026 | - | - | |
| 8-K | Jul 27, 2026 | - | Analysis | - |
| 8-K | Jul 23, 2026 | - | Analysis | - |
| 8-K | Jun 22, 2026 | - | Analysis | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 8-K | Apr 14, 2026 | - | Analysis | - |
Related Health Care companies
- FF · FutureFuel Corp.Industrial Organic Chemicals
- GEVO · Gevo, Inc.Industrial Organic Chemicals
- GPRE · Green Plains Inc.Industrial Organic Chemicals
- REX · REX AMERICAN RESOURCES CorpIndustrial Organic Chemicals
- SXT · SENSIENT TECHNOLOGIES CORPIndustrial Organic Chemicals
- VGAS · Verde Clean Fuels, Inc.Industrial Organic Chemicals
- SAFX · XCF Global, Inc.Industrial Organic Chemicals
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
CDXS SEC filings: frequently asked questions
Are CDXS insiders buying or selling?
In the last 90 days, CODEXIS, INC. (CDXS) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $30,558 by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CDXS stock?
As of September 30, 2026, the largest CODEXIS, INC. (CDXS) holders among the 13F filers tracked by SignalX were BlackRock ($11.6 million), Millennium Management ($6.6 million), Vanguard Capital Management LLC ($6.0 million), Ameriprise Financial ($4.2 million), D.E. Shaw & Co ($2.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CDXS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), CODEXIS, INC. (CDXS) reported revenue of $70.4 million (up 18.6% from FY2024) and a net loss of $44.0 million. Diluted EPS was -$0.50. The figures come from the XBRL data in the 10-K.
What did CDXS report in its latest 8-K?
CODEXIS, INC. (CDXS) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Codexis announced financial results for the quarter ended September 30, 2026.
What are the latest CDXS SEC filings?
CODEXIS, INC. (CDXS) filed its latest 10-K annual report on March 11, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 18, 2026.
What is CDXS's SEC CIK number?
CODEXIS, INC. (CDXS)'s SEC Central Index Key (CIK) is 1200375. EDGAR lists every CDXS filing under that number.
Ask anything about CDXS
The research agent reads CDXS's filings, financials, insider trades and 13F holders, then answers with sources.